奥沙利铂联合长春瑞滨一线治疗不可手术的非小细胞肺癌

Oxaliplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer

目的探讨奥沙利铂(OXA)联合长春瑞滨(VNB)一线治疗不可手术的非小细胞肺癌(NSCLC)的疗效与安全性。方法2003年2月～2003年12月,在我科住院的不可手术的NSCLC患者34例参加了本研究。其中,男性23例,女性11例;中位年龄为61岁;ECOG PS评分0～1/2分别为26/8例;ⅢB/Ⅳ期为13/21例;腺癌/非腺癌为18/16例。OXA130mg/m2+5%葡萄糖水静滴,第1天;VNB25mg/m2静注,第1、8天,每3周重复。2周期完成后,评价疗效和毒性,并随访生存期。结果OXA联合VNB治疗的客观缓解率为29%,中位生存期为10个月,1年生存率为41%。该方案血液学与非血液学不良反应均较轻,未出现Ⅲ～Ⅳ度血液学毒性;8例神经毒性为Ⅰ度。结论OXA联合VNB治疗晚期不可手术的NSCLC确切有效,毒副反应轻,安全性好。

Objective：To investigate efficacy and toxicity of oxaliplatin plus vinorelbine in advanced NSCLC. Methods：Thirty-four NSCLC chemo-naive patients hospitalized at our department （23 men, 11 women, median age 61, ECOG PS 0-1/2 26/8 ） entered the study,including 21 with stage Ⅳ disease and 18 with adenocarcinoma. Oxaliplatin（ 130mg/m^2） was dilated in 500ml of 5% glucose solution and administered in an intravenous infusion on day 1 and vinorelbine （25mg/m^2） was given as a 5-10min intravenous infusion on days 1 and 8. The regimen was repeated every 3 weeks. The efficacy and toxicity were evaluated after every two cycles of chemotherapy and survival was followed up. Results：Of the 34 patients, objective response rate of 29% was achieved. Median overall survival was 10 months with the 1-year survival rate of 41%. Hematological and non-hematological toxicities were comparatively low, without grade 3 - 4 of hematological toxicity. Eight patients experienced grade 1 neurosensory toxicity. Conclusion： Oxaliplatin/vinorelbine doublet is a safe and active regimen for advanced NSCLC.